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APTIMAAbstract We compared cytology with Hybrid Capture 2 (HC2), cobas, CLART and
APTIMA Human Papillomavirus (HPV) assays in primary cervical screening at age 23–
29 years based on data from the Danish Horizon study. SurePath samples were collected from
1278 women undergoing routine cytology-based screening. Abnormal cytology was managed
according to the routine recommendations, and women with cytology-normal/HPV-positive
samples were invited for repeated cytology and HPV testing in 1.5 years. Loss to follow-up
was similar between HPV assays. PCIN3 was detected in 44 women. The sensitivity of
HC2 for PCIN3 was 95% (95% conﬁdence interval (CI): 85–99), of cobas 98% (95% CI:
88–100), of CLART 100% (95% CI: 92–100), of APTIMA 82% (95% CI: 67–92), and of cytol-
ogy 59% (95% CI: 43–74). Speciﬁcity for PCIN3 varied between 61% (95% CI: 59–64) for
cobas and 75% (95% CI: 73–78) for APTIMA, and was 94% (95% CI: 93–96) for cytology.
Similar results were observed for PCIN2 (N = 68). HPV screening with cytological triage
doubled the number of colposcopies compared to cytology screening, and increased the fre-
quency of repeated testing by four (APTIMA) to seven (cobas) times. The positive predictive
value of a referral for colposcopy was relatively high for all screening tests (P30% for
PCIN3, and P50% for PCIN2). CIN1 was detected by cytology in 1% of women, and
in 2% by any of the four HPV assays. Although highly sensitive, HPV-based screening ofAlle´ 30,
jegod),
M. Rebolj et al. / European Journal of Cancer 51 (2015) 1456–1466 1457young Danish women should be approached cautiously, as it resulted in large reductions in
speciﬁcity, and increased the demand for additional testing.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human Papillomavirus (HPV) infections are frequent
in young women, but the majority clears spontaneously.
To avoid false-positive test results, HPV-based primary
cervical screening has been considered primarily for
women agedP30 years [1–4]. Nevertheless, some studies
suggested that certain HPV assays, particularly those
based on detection of HPV mRNA rather than DNA,
might be suitable for screening at younger ages. In the
French FASE (French APTIMA Screening Evaluation)
study, for example, 1109 women aged 20–29 years
attending routine cervical screening were tested with
ThinPrep liquid-based cytology (LBC), Hybrid Capture
2 (HC2) HPV DNA assay, and APTIMA HPV mRNA
assay [5]. In that study, APTIMA detected as many cases
of high-grade cervical intraepithelial neoplasia (CIN) as
HC2, whereas its speciﬁcity for high-grade CIN was sim-
ilar to that of LBC. However encouraging, these ﬁndings
should ideally be conﬁrmed by data from other studies.
Unfortunately, other studies comparing APTIMA with
HPV DNA assays in screening populations did not
present data speciﬁcally for this age group [6] or did
not ascertain histological results in women with positive
HPV tests and normal cytology [7].
Here, we presented data from the Danish Horizon
study using samples from 1278 women aged 23–29 years
attending primary cervical screening. All samples were
tested with SurePath LBC and four HPV assays
(APTIMA HPV Test (APTIMA; Hologic, San Diego,
CA), HC2 (QIAGEN, Gaithersburg, MD), cobas HPV
Test (cobas; Roche Diagnostics, Pleasanton, CA), and
CLART HPV2 Assay (CLART; Genomica, Madrid,
Spain)). We used these data to study the impact of the
ﬁve tests on screening sensitivity, speciﬁcity, proportions
of women with false-positive tests, and on colposcopy
referral rates in primary screening of young women.2. Materials and methods
2.1. Study design
The design of the Horizon study was described in
detail previously [8–12]. Consecutive SurePath samples
from 5034 women arriving for routine LBC analysis at
the Department of Pathology of Copenhagen
University Hospital, Hvidovre, in June–August 2011
were tested with the four HPV assays. By linkage to
the national Pathology Data Bank (Patobank) [13],primary screening samples were deﬁned as those without
a: previous cervical cancer, CIN in 63 years, atypical
squamous cells of undetermined signiﬁcance (ASCUS)
or non-CIN cervical biopsy in 615 months, or a more
severe cytological abnormality, inadequate cytology, or
a positive HPV test in 612 months. Approximately
10% of women aged 23–29 years living in the then-
catchment area of the laboratory were vaccinated
against HPV [14].
Danish women are recommended for routine cervical
screening every 3 years from age 23 onwards. Women
included in the Horizon study were managed in line with
their cytology and HPV test results, so that this setup
where cytology was the basis for routine clinical man-
agement also mimicked primary screening with HPV
testing and cytology triage. Women with abnormal
cytology, regardless of their HPV status, were managed
according to the routine Danish guidelines (repeated
cytology if ASCUS or low-grade squamous intraepithe-
lial lesions (LSIL), referral for colposcopy otherwise).
Women with a positive test result on at least one of
the four HPV assays at baseline and normal cytology
(i.e. triage-negative) were invited, for study purposes,
for repeated cytology and HPV testing in November
2012, approximately 1.5 years after the baseline. A
reminder was sent in March 2013.
Women who responded to the study follow-up invita-
tion had two SurePath samples taken. Those with
abnormal cytology or a positive HC2 test result (corre-
sponding to the routine HPV testing in the laboratory
at the time of the study) were recommended for col-
poscopy. Histology in women with follow-up outside
of the study was included in the analysis. All follow-
up outcomes were retrieved from the Patobank in
December 2013. This means that all histology was
ascertained in approximately 2.5 years after the baseline
testing, i.e. throughout most of the recommended 3-year
screening interval. Colposcopies were performed follow-
ing routine protocols recommending biopsies from all
suspicious areas, or random biopsies from the four
quadrants if lesions were not visible.
2.2. Cytology
Routine cytological evaluation was undertaken ﬁrst
by FocalPoint Slide Proﬁler (BD, Burlington, NC).
Blinded to the outcomes of HPV testing, samples were
thereafter evaluated by cytoscreeners using FocalPoint
GS Imaging System (BD), and abnormal ﬁndings were
adjudicated by pathologists.
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All assay testing was undertaken in strict accordance
with the protocols agreed upon with all manufacturers
prior to the study, described in detail previously
[8–12]. HC2 testing was undertaken on the post-quot
LBC material; cobas, CLART and APTIMA testing
were undertaken on the original residual material,
diluted approximately 1:1 in SurePath. HC2 detects 13
high-risk HPV genotypes [15] collectively. It is based
on hybridisation of HPV DNA to a high-risk HPV
RNA probe cocktail. No re-test range was used.
Cobas is a real-time PCR analysis detecting the 13
high-risk HPV genotypes and HPV66. The assay sepa-
rately identiﬁes HPV16 and HPV18, while the remaining
12 genotypes are detected collectively. CLART is a
PCR-based low density array assay individually report-
ing 35 deﬁned genotypes including the 13 high-risk.
APTIMA detects E6/E7 mRNA expression of the 13
high-risk HPV types and HPV66 collectively.2.4. Ethical considerations
Baseline testing of residual material was undertaken
as a quality development study. In Denmark, such
studies do not require ethical approval. Invitation to
follow-up of HPV-positive/cytology-normal women
was approved by the Ethics Committee of the Danish
Capital Region (H-4-2012-120). It was not permitted
to reveal the results of the baseline testing in the invita-
tion letter, but women could obtain them from their
general practitioner (GP). The study was notiﬁed to
the Danish Data Inspection Agency (notiﬁcation num-
ber 2010-41-5594).2.5. Statistical analysis
A positive HPV test result was deﬁned as relative
light units per cut-oﬀ valueP1.0 for HC2; cycle thresh-
old values 640.5, 640.0 and 640.0 for cobas’s channels
16, 18 and other high-risk, respectively; signal to cut oﬀ
P0.5 for APTIMA; and detection ofP1 of the 13 high-
risk genotypes by CLART. Abnormal cytology was
deﬁned as PASCUS.
A screening test’s clinical sensitivity was calculated as
the proportion of women with high-grade CIN (detected
at any point during the study) having a positive screening
test result at baseline, and clinical speciﬁcity as the pro-
portion of women who did not test positive among those
without high-grade CIN. A false-positive test result was
deﬁned as a positive test result at baseline not followed
by a diagnosis of high-grade CIN. We calculated the
relative sensitivity, speciﬁcity and the proportion of
false-positive tests by comparing the values to those of
the reference screening test (HC2 or cytology).
The 95% conﬁdence intervals (CI) for sensitivity andspeciﬁcity were calculated assuming binomial distribu-
tion; those for the relative indicators were calculated
assuming lognormal distribution. Persistent infection
was deﬁned as a (pooled) high-risk positive HPV test
result at baseline and at follow-up on the same HPV
assay. We calculated the positive predictive value (PPV)
of a persistent infection as the proportion of women with
a persistent infection having high-grade CIN.3. Results
3.1. Study population
At baseline, 1278 women had screening samples at
age 23–29 years (Table 1, Fig. 1). Ninety-ﬁve (7%) had
abnormal cytology. Whereas 681 (53%) had normal
cytology and negative test results on all four HPV
assays, 495 (39%) had normal cytology with a positive
test result on at least one assay. Test results were posi-
tive on HC2 for 406 (32%) of women, on cobas for
519 (41%), on CLART for 481 (38%) and on
APTIMA for 342 (27%).
Of the 95 women with abnormal baseline cytology,
six (6%) were lost to follow-up (Table 2). For 495 cytol-
ogy-normal/HPV-positive women, this was 247 (50%);
158 (32%) had study follow-up (Table 3) and 90 (18%)
had other follow-up. The completeness of follow-up
did not diﬀer substantially by HPV assay.
Of the 158 women with repeated testing in 1.5 year
within the study (mean = 18.0 months, SD =
1.4 month), 15 (9%) developed abnormal cytology.
Persistent infections, i.e. a positive (pooled) high-risk
HPV test result followed by another (pooled) high-risk
positive HPV test result in 1.5 years, were observed in
69 (62%) of 112 women with a baseline positive HC2
result, 85 (61%) of 140 women positive on cobas, 63
(48%) of 130 positive on CLART and 45 (48%) of 94
women positive on APTIMA. PPV for PCIN2 of per-
sistent HPV infections were 30–40%, and 50% for
incident abnormal cytology.
3.2. Sensitivity and speciﬁcity for high-grade CIN
Of the 44PCIN3, HC2 detected 42 (sensitivity: 95%,
95% CI: 85–99; Table 4). Cobas detected 43, sensitivity:
98% (95% CI: 88–100), CLART 44 (100%, 95% CI: 92–
100), APTIMA 36 (82%, 95% CI: 67–92) and cytology
26 (59%, 95% CI: 43–74). APTIMA and cytology
detected statistically signiﬁcantly fewer PCIN3 than
HC2, cobas and CLART. Speciﬁcity forPCIN3 varied
between 61% (95% CI: 59–64) for cobas and 75% (95%
CI: 73–78) for APTIMA; it was 94% (95% CI: 93–96)
for cytology. The diﬀerences were signiﬁcant, with lower
speciﬁcity for cobas and CLART, and higher for
APTIMA, compared to HC2. The results for PCIN2
(N = 68) were similar.
Table 1
Description of the 1278 women aged 23–29 years with screening
samples at baseline.
Characteristics at baseline N (%)
Total 1278
(100%)
Age (years)
23 339 (27%)
24 92 (7%)
25 123 (10%)
26 246 (19%)
27 138 (11%)
28 135 (11%)
29 205 (16%)
Cytological diagnosis
Inadequate 6 (<1%)
Normal 1177 (92%)
ASCUS 16 (1%)
LSIL 49 (4%)
AGC, ASC-H, AIS, HSIL, or carcinoma 30 (2%)
HPV test results
Positive on HC2 406 (32%)
Positive on cobas 519 (41%)
Positive on CLART 481 (38%)
Positive on APTIMA 342 (27%)
Combined cytology and HPV results
Cytology normal and all 4 HPV test results negative 681 (53%)
Cytology normal and at least one HPV test result
positivea
495 (39%)
Cytology abnormal, regardless of HPV test results 95 (7%)
Otherb 7 (1%)
Abbreviations: AGC, atypical glandular cells; AIS, adenocarcinoma
in situ; ASCUS, atypical squamous cells of undetermined signiﬁcance;
ASC-H, atypical squamous cells cannot exclude HSIL; HC2, Hybrid
Capture 2; HPV, Human Papillomavirus; HSIL, high-grade squamous
intraepithelial lesions; LSIL, low-grade squamous intraepithelial
lesions.
a Invited for repeated testing at 18 months according to the study
protocol.
b Inadequate cytology, or normal cytology with at least one invalid
HPV test result and no positive HPV test result.
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In total, 7% of women were recommended for follow-
up because of abnormal cytology (Table 5). With stand-
alone HPV testing, this proportion was between 27%
with APTIMA and 41% with cobas, i.e. about four to
six times higher than with cytology.
With cytology-based screening, 5% of women were
referred for colposcopy and 2% needed only repeated
testing. With HPV assays combined with cytological
triage, about twice as many had colposcopy. The PPV
of a referral for colposcopy was relatively high for all
ﬁve screening tests (30% for PCIN3, 50% for
PCIN2, Table 6). The frequency of repeated testing
was four times higher with APTIMA and HC2 com-
pared to cytology, six times higher with CLART and
seven times higher with cobas.
CIN1 was detected by cytology in 1% of women,
and by any of the four HPV assays in 2%; HC2, cobasand CLART led to a statistically signiﬁcant increase in
CIN1 detection compared to cytology. Detection of
PCIN3 was between 60% and 70% higher and of
PCIN2 around 90% higher for the three HPV DNA
assays compared to cytology. APTIMA detected more
high-grade CIN than cytology (38%), but the diﬀerence
was not signiﬁcant.
As 2.0% of women screened with cytology had
PCIN3 detected, 5% had a false-positive cytology test.
Using any of the four HPV assays, this proportion
was statistically signiﬁcantly higher, and ranged from
24% with APTIMA to 37% with cobas.4. Discussion
4.1. General ﬁndings
Follow-up of young, mostly unvaccinated, Danish
women with normal cytology and positive HPV test
results on HC2, cobas, CLART or APTIMA substan-
tially increased the overall detection of both PCIN2
(by 70–90%) and PCIN3 (by 40–70%) compared to
cytology alone. Not surprisingly, the increased sensitiv-
ity was mirrored by a substantial decrease in screening
speciﬁcity. Even with cytological triage of women with
positive HPV tests, about twice as many were referred
for colposcopy, and between four and seven times as
many had a false-positive test compared to cytology
alone. To this end, the lowest increases in the detection
of CIN, false-positive tests and referrals to colposcopy
were observed for the HPV mRNA assay APTIMA.4.2. Strengths and weaknesses
Horizon was one of the few studies comparing several
HPV assays in the same women while also ascertaining
the clinical outcomes after cytology-normal/HPV-posi-
tive test results. The studied women were representatives
for the routine screening population [10], and the
samples were tested while fresh [9,11].
Of women with cytology-normal/HPV-positive test
results at baseline, 50% had follow-up. Had the fol-
low-up been complete, more high-grade CIN lesions
would have been detected on account of HPV testing
in cytology-normal women. This would increase the
calculated diﬀerences in the sensitivity of HPV assays
and cytology. However, the gap between the proportion
of women with positive screening test results and the
detection of high-grade CIN was so large that the
incomplete follow-up cannot explain the high propor-
tions of false-positive tests (data not reported).4.3. Comparison with the literature
The substantially higher sensitivity for high-grade
CIN in young women for HPV testing compared to
Fig. 1. Description of the study. *Women with normal cytology. **Other: Human Papillomavirus (HPV) negative on all four tests or with
inadequate cytology. There were six women with inadequate cytology, of whom four had normal cytology in follow-up, and two had normal
histology. One woman with normal cytology and four negative HPV test results had CIN2 in follow-up.
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randomised controlled trials comparing primary
HPV-based screening (using HC2) with cytology-based
screening, the proportions of women with false-positive
test results for PCIN3 varied between 12–17% at
25–34 years in Italy and Finland, and 31% at
20–29 years in the United Kingdom (UK) [17].
Proportions of women referred for colposcopy were gen-
erally not reported, except in the Italian NTCC Phase 1
trial [4,18]. There, the management at age 25–34 years
after a positive HC2 test result was similar as in our
study, with repeated testing in 12 months. Women were
about twice as often referred for colposcopy with HC2
than with cytology. They also had three times as many
false-positive tests with HC2, and were 11 times more
likely referred for repeated testing [19]. These NTCC
data were consistent with ours in pointing to a higher
average number of health care contacts per woman
screened with HPV testing than with cytology, at least
in the initial HPV screening round.
One of the most frequently reported indicators of
speciﬁcity from the trials was the PPV of a colposcopy
referral. Like in our study, the PPV of HPV-based
screening with cytological triage tended to be similar
to that of cytology-based screening [20]. Yet, about
twice as many women without high-grade CIN had col-
poscopy following HPV testing than following cytology
screening alone.
Detection of HPV mRNA instead of DNA has been
considered a viable and most likely a safe strategy toreduce the high numbers of false-positive HPV screening
tests [21]. The use of APTIMA in primary screening was
evaluated in several studies [5–7,22,23]. As mentioned
earlier, APTIMA was compared to LBC and HC2 in
1109 women aged 20–29 years in the FASE study [5].
Contrary to our ﬁndings, in French women APTIMA
was as sensitive for high-grade CIN as HC2, but as
speciﬁc as cytology. Among French women, 13.5%
had abnormal cytology, whereas 23.5% tested positive
on HC2, and 15.6% on APTIMA (relative proportion
of positive test results for APTIMA versus HC2: 0.66).
This diﬀerence between APTIMA and HC2 was less
pronounced in our study, where the relative proportion
of positive test results was 0.84. The FASE study used
ThinPrep samples, and women with inadequate cytology
(10.5%) were excluded from the analysis. Moreover, any
diﬀerence in the background risk for cervical cancer,
however unmeasured, between the French study and
ours may have played a role, and suggested that the
trade-oﬀs between the detection and the burden by the
diﬀerent screening technologies may be population-
speciﬁc.
In our study, APTIMA tended to detect fewer high-
grade CIN than the three DNA assays. As the lower
detection was conﬁned to young women [24], a plausible
interpretation might be a lower degree of over-diagnosis
compared to HPV DNA assays [4,25]. mRNA assays
are in principle designed to detect transcriptionally
active HPV infections. By measuring only transcription-
ally active/integrated HPV infections, transient, recent
Table 2
Follow-up outcomes for women with positive screening test results at baseline.
Baseline screening test Total N at
baseline
(column%)
Worst outcome during follow-up (row%)
Cytology test result HPV test result No follow-up No histology Histology
Normal cytology and/or
negative HPV testing
Abnormal cytology
and/or positive HPV
testing
Inadequate
histology
No CIN (CIN 0) CIN1a CIN2 CIN3b
Normal or abnormal (total) Negative or
positive (total)
1278 (100%) 804 (63%) 279 (22%) 32 (3%) 6 (<1%) 61 (5%) 28 (2%) 24 (2%) 44 (3%)
Cytology
Abnormal Any 95 (7%) 6 (6%) 22 (23%) 4 (4%) 2 (2%) 16 (17%) 11 (12%) 8 (8%) 26 (27%)
Normal P1 Positive 495 (39%) 247 (50%) 137 (28%) 23 (5%) 4 (1%) 34 (7%) 17 (3%) 15 (3%) 18 (4%)
HC2
Normal or abnormal Positive 406 (32%) 152 (37%) 101 (25%) 22 (5%) 6 (1%) 36 (9%) 25 (6%) 22 (5%) 42 (10%)
Normal Positive 314 (25%) 146 (46%) 80 (25%) 18 (6%) 4 (1%) 20 (6%) 14 (4%) 14 (4%) 18 (6%)
Abnormal Positive 91 (7%) 6 (7%) 21 (23%) 4 (4%) 2 (2%) 15 (16%) 11 (12%) 8 (9%) 24 (26%)
Cobas
Normal or abnormal Positive 519 (41%) 215 (41%) 138 (27%) 27 (5%) 6 (1%) 41 (8%) 27 (5%) 22 (4%) 43 (8%)
Normal Positive 432 (34%) 211 (49%) 117 (27%) 23 (5%) 4 (1%) 29 (7%) 16 (4%) 14 (3%) 18 (4%)
Abnormal Positive 87 (7%) 4 (5%) 21 (24%) 4 (5%) 2 (2%) 12 (14%) 11 (13%) 8 (9%) 25 (29%)
CLART
Normal or abnormal Positive 481 (38%) 199 (41%) 127 (26%) 24 (5%) 6 (1%) 35 (7%) 23 (5%) 23 (5%) 44 (9%)
Normal Positive 396 (31%) 194 (49%) 109 (28%) 20 (5%) 4 (2%) 23 (6%) 13 (3%) 15 (4%) 18 (5%)
Abnormal Positive 85 (7%) 5 (6%) 18 (21%) 4 (5%) 2 (2%) 12 (14%) 10 (12%) 8 (9%) 26 (31%)
APTIMA
Normal or abnormal Positive 342 (27%) 128 (37%) 82 (24%) 19 (6%) 6 (2%) 27 (8%) 22 (6%) 22 (6%) 36 (11%)
Normal Positive 261 (20%) 123 (47%) 64 (25%) 15 (6%) 4 (2%) 15 (6%) 12 (5%) 14 (5%) 14 (5%)
Abnormal Positive 81 (6%) 5 (6%) 18 (22%) 4 (5%) 2 (2%) 12 (15%) 10 (12%) 8 (10%) 22 (27%)
Abbreviations: CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV, Human Papillomavirus.
a Includes atypia on histology and CIN not otherwise speciﬁed.
b No woman had cervical cancer.
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Table 3
Women with normal cytology and at least one positive HPV test result at baseline (n = 495): 1.5-year persistence of infection, and ﬁnal histology in
158 women with repeated cytology and HPV testing, by HPV assay.
Screening test Cytology normal and HPV positive at baseline Women with persistent infections/ incident abnormal cytology
Total With 18-month follow-up (%) N (% of those
with follow-up)
PCIN2 (% of those
with persistent infection)
PCIN3 (% of those
with persistent infection)
Cytology 495a (100%) 158 (32%) 15 (9%) 8 (53%) 4 (27%)
HC2 314 (100%) 112 (36%) 69 (62%) 26 (38%) 13 (19%)
Cobas 432 (100%) 140 (32%) 85 (61%) P25 (P29%)b P13 (P16%)b
CLART 396 (100%) 130 (33%) 63 (48%) P25 (P40%)b P12 (P19%)b
APTIMA 261 (100%) 94 (36%) 45 (48%) P20 (P44%)b P11 (P19%)b
Abbreviations: CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV, Human Papillomavirus.
a A positive test result on any of the four HPV assays.
b Only women with abnormal cytology and/or a positive HC2 test result were referred for colposcopy.
Table 4
Sensitivity and speciﬁcity of HPV assays and cytology, and relative sensitivity and speciﬁcity compared to Hybrid Capture 2, for detection of
PCIN3 and PCIN2, in women aged 23–29 years undergoing primary cervical screening.
Sensitivity (95% CI) Relative sensitivity (95% CI) Speciﬁcity (95% CI) Relative speciﬁcity (95% CI)
Endpoint: PCIN3
HC2 95% (85–99) 1.00 (Ref) 71% (68–73) 1.00 (Ref)
Cobas 98% (88–100) 1.02 (0.95–1.11) 61% (59–64) 0.87 (0.82–0.92)
CLART 100% (92–100) 1.05 (0.98–1.12) 65% (62–67) 0.92 (0.87–0.97)
APTIMA 82% (67–92) 0.86 (0.74–1.00) 75% (73–78) 1.07 (1.02–1.12)
Cytology 59% (43–74) 0.62 (0.48–0.80) 94% (93–96) 1.34 (1.29–1.39)
Endpoint: PCIN2
HC2 94% (86–98) 1.00 (Ref) 72% (69–74) 1.00 (Ref)
Cobas 96% (88–99) 1.02 (0.94–1.10) 62% (60–65) 0.87 (0.82–0.92)
CLART 99% (92–100) 1.05 (0.98–1.12) 66% (63–68) 0.92 (0.87–0.97)
APTIMA 85% (75–93) 0.91 (0.81–1.02) 77% (74–79) 1.07 (1.02–1.12)
Cytology 50% (38–62) 0.53 (0.42–0.68) 95% (94–96) 1.32 (1.27–1.37)
Abbreviations: CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2.
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HPV infections are theoretically avoided. It can be
hypothesised that CIN missed by APTIMA but detected
by an HPV DNA assay tended to be those that would
have spontaneously regressed if left untreated, which is
often the case in younger women [26]; however, this
hypothesis is hard to prove. For now, the relative pro-
gression potential of HPV mRNA-negative/HPV
DNA-positive high-grade CIN is unknown, and leaving
these lesions untreated would be unethical.
4.4. Clinical implications
Despite screening since the 1960’s, the incidence rate
in Danish women aged 25–29 years remains around 12/
100,000 women [27]. Although highly sensitive HPV
assays would probably improve the protection from cer-
vical cancer, they would unlikely eradicate the disease at
young age [28]. Furthermore, there is a downside to
detecting CIN lesions particularly in women of child-
bearing age, as their treatment may be associated with
an increased risk of poorer pregnancy outcomes [29–
31]. This is particularly problematic given that many
high-grade CIN detected at young age do not tend toprogress to cervical cancer [26,32]. Furthermore, a pos-
itive HPV test result induces a psychological burden
[33,34], and may reduce sexual satisfaction [35].
The challenge, therefore, is to detect and triage to col-
poscopy only those HPV infections that have a real
chance of progressing to cervical cancer. Although a
careful selection of women for a referral for colposcopy
can on its own not resolve the problem of low speciﬁcity
of the screening test, colposcopy referral should be opti-
mised with respect to its frequency and CIN detection.
Based on the data from the Horizon study, we made
some basic post hoc comparisons of the proportions of
referred women and CIN detection at baseline for likely
triage strategies. In interpreting the outcomes of this
post hoc analysis, it should be taken into account that
HPV-positive women were in reality managed through
cytology triage, and also that in a true routine HPV-
based screening setting the performance of cytology as
a triage test might change. With cytology triage of
HPV-positive women, 6–7% of all screened women
would be referred for colposcopy at baseline (Table 7),
and the remainder with positive HPV test results for fol-
low-up with repeated testing (which would include a
referral in case of abnormal ﬁndings). This strategy
Table 5
Consequences of replacing cytology with either of the four HPV assays combined with cytology triage in primary cervical cancer screening of women below age 30 years (N = 1278).
Abnormal/positive
test results
Follow-up proceduresa Detection of CIN False-positive test results
Colposcopyb Repeated
testing only
CIN1c PCIN2 PCIN3 Endpoint: PCIN2 Endpoint: PCIN3
Absolute numbers, N (%)
Cytology 95 (7%) 63 (5%) 26 (2%) 11 (0.9%) 34 (2.7%) 26 (2.0%) 61 (5%) 69 (5%)
HC2 406 (32%) 131 (10%) 123 (10%) 25 (2.0%) 64 (5.0%) 42 (3.3%) 342 (27%) 364 (28%)
Cobas 519 (41%) 139 (11%) 165 (13%) 27 (2.1%) 65 (5.1%) 43 (3.4%) 454 (36%) 476 (37%)
CLART 481 (38%) 131 (10%) 151 (12%) 23 (1.8%) 67 (5.2%) 44 (3.4%) 414 (32%) 437 (34%)
APTIMA 342 (27%) 113 (9%) 101 (8%) 22 (1.7%) 58 (4.5%) 36 (2.8%) 284 (22%) 306 (24%)
Relative risk (95% CI)
Cytology 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
HC2 4.27 (3.47–5.27) 2.08 (1.56–2.78) 4.73 (3.12–7.17) 2.27 (1.12–4.60) 1.88 (1.25–2.83) 1.62 (1.00–2.62) 5.61 (4.32–7.28) 5.28 (4.13–6.74)
Cobas 5.46 (4.45–6.70) 2.21 (1.66–2.94) 6.35 (4.23–9.53) 2.45 (1.22–4.93) 1.91 (1.27–2.87) 1.65 (1.02–2.67) 7.44 (5.76–9.61) 6.90 (5.43–8.77)
CLART 5.06 (4.12–6.22) 2.08 (1.56–2.78) 5.81 (3.86–8.74) 2.09 (1.02–4.27) 1.97 (1.31–2.96) 1.69 (1.05–2.73) 6.79 (5.25–8.78) 6.33 (4.97–8.07)
APTIMA 3.60 (2.91–4.46) 1.79 (1.33–2.42) 3.88 (2.54–5.94) 2.00 (0.97–4.11) 1.71 (1.13–2.59) 1.38 (0.84–2.28) 4.66 (3.57–6.07) 4.43 (3.46–5.69)
Abbreviations: CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2.
a The diﬀerence between the total number of women with positive screening test results and women with either colposcopy or repeated testing only were women who had no follow-up.
b Measured as registered with a biopsy in the Patobank.
c Includes CIN1, histological atypia and CIN NOS.
Table 6
Positive predictive value of colposcopy.
Screening test Colposcopy (%) Endpoint: PCIN2 Endpoint: PCIN3
N detected (PPV
of colposcopy)
Relative
PPV (95% CI)
N FP colposcopy
(% of all screened women)
RR of FP
colposcopy (95% CI)
N detected
(PPV of
colposcopy)
Relative
PPV (95% CI)
N FP colposcopy
(% of all screened
women)
RR of FP
colposcopy
(95% CI)
Cytology 63 (100%) 34 (54%) 1 (ref) 29 (2%) 1 (ref) 26 (41%) 1 (ref) 37 (3%) 1 (ref)
HC2 131 (100%) 64 (49%) 0.91 (0.68–1.21) 67 (5%) 2.3 (1.5–3.5) 42 (32%) 0.78 (0.53–1.14) 89 (7%) 2.4 (1.7–3.5)
Cobas 139 (100%) 65 (47%) 0.87 (0.65–1.16) 74 (6%) 2.6 (1.7–3.9) 43 (31%) 0.75 (0.51–1.10) 96 (8%) 2.6 (1.8–3.8)
CLART 131 (100%) 67 (51%) 0.95 (0.71–1.26) 64 (5%) 2.2 (1.4–3.4) 44 (34%) 0.81 (0.56–1.19) 87 (7%) 2.4 (1.6–3.4)
APTIMA 113 (100%) 58 (51%) 0.95 (0.71–1.27) 55 (4%) 1.9 (1.2–3.0) 36 (32%) 0.77 (0.52–1.15) 77 (6%) 2.1 (1.4–3.1)
Abbreviations: CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; FP, false-positive; PPV, positive predictive value; RR, relative risk.
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1464 M. Rebolj et al. / European Journal of Cancer 51 (2015) 1456–1466would detect just over half of all PCIN2 already at
baseline, leaving the remaining half to be detected
through repeated testing. If, instead, triage were under-
taken using limited genotyping for HPV16 and 18, 16%
of all young screened women would be referred for col-
poscopy at baseline. This triage strategy would detect
slightly more high-grade CIN at baseline than cytologi-
cal triage. In young Danish women with normal cytol-
ogy, progression to PCIN3 was most frequent for
women persistently infected with HPV16 (cumulative
12-year PCIN3 incidence: ca. 27%), HPV18, HPV31,
or HPV33 (15–20%) [36]. If triage was undertaken by
genotyping for these four genotypes on CLART, 23%
of screened women would be referred, however, approx-
imately 90% of all high-grade CIN could be detected
already at baseline. Combining genotyping with cytol-
ogy as triage tests would refer to colposcopy relatively
few women at baseline, but leave relatively large propor-
tions of CIN to be detected at follow-up. Finally, triag-
ing positive HPV DNA test results with a positive HPV
mRNA test result or vice versa would refer to col-
poscopy about a quarter of all young screened women
but would detect close to 90% of all high-grade CIN
at baseline. A more detailed analysis of optimal triage
strategies is on-going, and will be reported separately.
In conclusion, HPV-based screening of young Danish
women with DNA or mRNA assays should be
approached with caution. The gains in the detection of
high-grade CIN tended to be obtained through large
reductions in screening speciﬁcity, and increases in the
demand for additional testing.
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